← SynDRA
MARIBAVIR
SynDRA canonical compound SYN0018861 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | PYGM |
|---|
| Mechanism of action | cytomegalovirus inhibitor | protein kinase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- cytomegalovirus inhibitor
- protein kinase inhibitor
- CMV UL97 INHIBITOR
- UL97 INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
Drug classes
- Anti-Infective Agents
- Antiviral Agents
- Cytochrome P450 3A4 Inhibitors
- P-Glycoprotein Inhibitors
- Breast Cancer Resistance Protein Inhibitors
- Cytomegalovirus pUL97 Kinase Inhibitor
- Cytomegalovirus pUL97 Kinase Inhibitors
ATC classes
- J05A · DIRECT ACTING ANTIVIRALS
Cross-references
Synonyms
- LIVTENCITY
- Livtencity
- livtencity
- 1263-W-94
- 1263W94
- BW-1263W94
- GW-257406X
- Benzimidavir
- UNII-PTB4X93HE1
- PTB4X93HE1
- Maribavir [USAN:INN:BAN]
- Camvia
- C15H19Cl2N3O4
- Camvia(TM)
- Camvia (TN)
- Bzurea
- SHP620
- TAK620
- BW 1263W94
- GW 257406X
- GW 1263
- GW257406X
- maribavirum
- RefChem:57686
- DTXCID0092582
- J05AX10
- Benzimidazol-2-amine
- G1263
- Maribavir [USAN]
- Livtencity (TN)
- Maribavir (Standard)
- MARIBAVIR [INN]
- MARIBAVIR [WHO-DD]
- Maribavir (JAN/USAN/INN)
- SCHEMBL791309
- orb1306272
- SCHEMBL29712054
- GTPL12049
Reported adverse events
- Fatigue
- Nausea
- Vomiting
- Infection
Look up MARIBAVIR in the interactive SynDRA portal →